ELEVAI LABS INC. - COMMON STOCK

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

01 май 2024 09:00:00 Источник Nasdaq GlobeNewswire

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

29 апр 2024 09:46:12 Источник Nasdaq GlobeNewswire

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

22 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

29 мар 2024 12:00:00 Источник Nasdaq GlobeNewswire

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market

18 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire

ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office

24 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

17 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

16 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire

ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences

02 янв 2024 09:15:00 Источник Nasdaq GlobeNewswire

Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023

11 дек 2023 09:15:00 Источник Nasdaq GlobeNewswire

ELEVAI Labs, Inc. Expands International Distribution into Europe

07 дек 2023 09:41:56 Источник Nasdaq GlobeNewswire

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

29 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire